Lorenzo Bertani

37PUBLICATIONS
130CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Rheumatology and arthritisEnvironmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Mar 14, 2026
Response to Letter to the Editor: "Enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis".

Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa

|Feb 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Franco Scaldaferri, Federica Di Vincenzo, Marina Aloi

|Dec 05, 2025
Reply: "Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care".

Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa

|Nov 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Giammarco Mocci, Antonio Tursi, Franco Scaldaferri

|Oct 24, 2025
The Impact of E-Cigarettes and Heat-Not-Burn Tobacco on Postoperative Recurrence of Crohn's Disease: A Multicenter International Study.

Tommaso Lorenzo Parigi, Olga Maria Nardone, Maria Lisa

|Sep 07, 2025
When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.

Lorenzo Bertani, Davide Giuseppe Ribaldone, Fabrizio Bossa

Pageof 7

Frequent Collaborators

9 joint publications

Edoardo Vincenzo Savarino

8 joint publications

Davide Giuseppe Ribaldone

5 joint publications

Massimo Bellini

5 joint publications

Fabiana Zingone